We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Diagnostic Blood Test More than Halves Hospital Length of Stay for Heart Failure Patients

By HospiMedica International staff writers
Posted on 04 Oct 2022
Print article
Image: New data shows heart failure treatment guided by Daxor’s BVA-100 lowers hospital length of stay by 55% (Photo courtesy of Daxor)
Image: New data shows heart failure treatment guided by Daxor’s BVA-100 lowers hospital length of stay by 55% (Photo courtesy of Daxor)

Effective management of patients hospitalized for heart failure remains problematic despite advances in medical therapy. Hospitals and clinicians struggle with readmissions, mortality and wasted resources. There is a need for accurate, actionable data to allow clinicians to optimize treatment plans and individualize care, thereby improving outcomes and reducing duration and cost of care. Now, new data has validated the benefits of a diagnostic blood test in reducing hospital length of stay (LOS) for heart failure patients.

Daxor Corporation’s (Oak Ridge, TN, USA) BVA-100 (Blood Volume Analyzer) is the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment.

In the latest study titled “Length of Stay After Blood Volume Analysis in Hospitalized Heart Failure” compared both hospital admission and discharge dates, allowing the calculation of pre- and post-BVA LOS for all patients. Those who received BVA-guided treatment on the day of admission to the hospital had a highly significant (p <0.001) lower total LOS than controls (2.04 vs. 4.56 days) and significantly improved outcomes (lower 30-day readmissions and 365-day mortality).

“This important study shows that BVA has the ability to help clinicians treat patients more effectively so that they get out of the hospital faster and have better results in terms of mortality and readmission when compared to those who did not receive BVA-guided care. Annual costs for HF treatment are estimated at USD 30.7 billion and expected to grow to nearly USD 70 billion by 2030 if we fail to improve on current treatment outcomes. Notably, in-hospital care comprises the majority of costs across all HF categories, averaging USD 14,000 per admission,” stated Michael Feldschuh, CEO and President of Daxor Corporation.

“The clinical evidence continues to demonstrate that our innovative BVA-100 blood test uniquely allows physicians to understand underlying HF blood volume derangements, providing them with accurate, actionable data to individualize treatment plans in both the inpatient and outpatient settings - improving outcomes and reducing the total cost of care,” added Jonathan Feldschuh, Chief Scientific Officer of Daxor Corporation.

Related Links:
Daxor Corporation 

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Remote Controlled Digital Radiography and Fluoroscopy System
Eco Track-DRF - MARS 50/MARS50+/MARS 65/MARS 80

Print article

Channels

Critical Care

view channel
Image: The stretchable microneedle electrode arrays (Photo courtesy of Zhao Research Group)

Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment

The field of personalized medicine is transforming rapidly, with advancements like wearable devices and home testing kits making it increasingly easy to monitor a wide range of health metrics, from heart... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more